INTRODUCTION {#s1}
============

Lung cancer is the leading cause of cancer deaths and results in more than one million deaths worldwide annually \[[@R1]\]. Approximately 150,000 deaths occur in the USA annually \[[@R2]\], with an estimated 16.8% of patients surviving 5 years or longer. While rates of new cases and deaths have fallen steadily in recent years, these declines have been slow and small in magnitude compared with other cancers. Therefore, the prevention and treatment of lung cancer remain unmet needs. However, chemoprevention trials for lung cancer have yielded negative results \[[@R3]\], and the currently available protocols for lung cancer treatment including conventional chemotherapy, radiotherapy, and molecularly targeted therapy appear to have minimal benefits for improving the survival of lung cancer patients \[[@R4]\]. The identification of key biomarkers with prognostic value would help guide future clinical trials of lung cancer therapies.

Type 1 insulin-like growth factor receptor (IGF-1R), a membrane-associated receptor tyrosine kinase, plays a clear role in cell proliferation, survival, transformation, angiogenesis, and invasion \[[@R5]\]. Deregulation of IGF signaling has been described in several cancer types, including both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) \[[@R6]\], and high expression of IGF-1R in NSCLC has been reported \[[@R7], [@R8]\]. The therapeutic value of an IGF-1R antibody has also been assessed in recent trials. Figitumumab, which targets IGF-1R, initially exhibited promising efficacy against advanced NSCLC in a phase II study \[[@R9]\], but failed to exhibit safety and efficacy in a phase III trial, and further clinical development was stopped \[[@R10]\]. Furthermore, preclinical and clinical studies do not consistently support the predictive or prognostic value of IGF-1R expression in NSCLC \[[@R7], [@R11]-[@R13]\].

Because previous studies have reported a potential role of IGF-1R pathways in lung cancer \[[@R14]\], we analyzed the expression of phospho-IGF-1R and IGF-1R in NSCLC biopsy samples using two large repositories of tissues annotated for relevant histological and clinical variables. We then assessed the relationship of these markers with lung cancer survival. In addition, alterations in IGF-1R mRNA and protein expression and their relationships with overall survival (OS) and disease-free survival (DFS) were evaluated using data from The Cancer Genome Atlas (TCGA).

RESULTS {#s2}
=======

Expression of IGF-1R and pIGF-1R {#s2_1}
--------------------------------

We performed an IHC analysis of IGF-1R and pIGF-1R (Y1135/36) expression using two TMAs. Expression levels of cytoplasmic and membranous location were well-correlated for each marker. Representative IHC results are shown in Fig. [1](#F1){ref-type="fig"}. Similar to previous findings, IGF-1R expression was primarily cytoplasmic (Figs. [2A and 2B](#F2){ref-type="fig"}) and significantly higher in patients with SCC compared to ADC in both TMAs (Figs. [2A and 2B](#F2){ref-type="fig"}). The cytoplasmic expression levels of pIGF-1R were also significantly higher in patients with SCC than ADC in both of the TMAs, while the membranous pIGF-1R expression level was significantly associated with SCC only in TMA II (Figs. [2A and 2B](#F2){ref-type="fig"}). The expression levels of the biomarker were not significantly different between stages (data not shown).

![Representative photomicrographs of the immunohistochemical analysis of IGF-1R and phospho-IGF-1R protein expression in histological tissue sections of adenocarcinoma (ADC) and squamous cell carcinoma (SCC)](oncotarget-06-16746-g001){#F1}

###### Increased expression of IGF-1R and phospho-IGF-1R in SCC compared to ADC

(**A**) TMA I and (**B**) TMA II. ADC: adenocarcinoma, SCC: squamous cell carcinoma. P-values were calculated using the Mann--Whitney test.
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###### Patients characteristics in tissue microarray (TMA) dataset I

  Characteristic                                             TMA I (N=352)
  ---------------------------------------------------------- ---------------
  Median age                                                 
   Years (Range)                                             66 (34-90)
  Gender                                                     
   Female                                                    189 (53.7%)
   Male                                                      160 (45.5%)
  Histology                                                  
   Adenocarcinoma                                            231 (65.6%)
   Squamous cell carcinoma                                   121 (34.3%)
  Ethnicity                                                  
   Caucasian                                                 313 (88.9%)
   Asian                                                     14 (4.0%)
   African American                                          15 (4.3%)
   Hispanic                                                  10 (2.8%)
  Smoking status[\*](#tfn_001){ref-type="table-fn"}          
   Never                                                     63 (17.9%)
   Former                                                    174 (49.4%)
   Current                                                   114 (32.4%)
   Unknown                                                   1 (0.3%)
  Pathological T stage^[†](#tfn_002){ref-type="table-fn"}^   
   T1                                                        130 (36.9%)
   T2                                                        185 (52.6%)
   T3                                                        18 (5.1%)
   T4                                                        20 (5.7%)
  Pathological N stage^[†](#tfn_002){ref-type="table-fn"}^   
   N0                                                        253 (71.9%)
   N1                                                        60 (17.0%)
   N2                                                        39 (11.1%)
   Nx                                                        
  Final Stage^[†](#tfn_002){ref-type="table-fn"}^            
   I                                                         225 (63.9%)
   II                                                        65 (18.5%)
   III                                                       50 (14.2%)
   IV                                                        12 (3.4%)

Smoking history was assigned based on the CDC definitions (Accessed on Jun 29, 2010. <http://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm>)

Never smoker: An adult who has never smoked, or who has smoked less than 100 cigarettes in his or her lifetime. Former smoker: An adult who has smoked at least 100 cigarettes in his or her lifetime but who had quit smoking at the time of interview. Current smoker: An adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes.

According to the American Joint Committee on Cancer Staging Manual 6th edition.

###### Patients characteristics in tissue microarray (TMA) dataset II

  Characteristic                                             TMA II (N=353)
  ---------------------------------------------------------- ----------------
  Median age                                                 
   Years (Range)                                             66 (34-90)
  Gender                                                     
   Female                                                    174 (49.3%)
   Male                                                      179 (50.7%)
  Histology                                                  
   Adenocarcinoma                                            227 (64.3%)
   Squamous cell carcinoma                                   126 (35.7%)
  Ethnicity                                                  
   Caucasian                                                 316 (89.5%)
   Asian                                                     5(1.4%)
   African American                                          18 (5.1%)
   Hispanic                                                  14 (4%)
  Smoking status[\*](#tfn_003){ref-type="table-fn"}          
   Never                                                     38 (10.8%)
   Former                                                    164 (46.5%)
   Current                                                   151 (42.8%)
   Unknown                                                   
  Pathological T stage^[†](#tfn_004){ref-type="table-fn"}^   
   T1                                                        131(37.1%)
   T2                                                        202(57.2%)
   T3                                                        20(5.7%)
  Pathological N stage^[†](#tfn_004){ref-type="table-fn"}^   
   N0                                                        236 (67.6%)
   N1                                                        66 (18.9%)
   N2                                                        47 (13.5%)
  Final Stage^[†](#tfn_004){ref-type="table-fn"}^            
   IA                                                        100 (28.3%)
   IB                                                        125 (35.4%)
   IIA                                                       22 (6.2%)
   IIB                                                       49 (13.9%)
   IIIA                                                      57(16.1%)
  Adjuvant treatment                                         
   No                                                        216 (61.2%)
   Yes                                                       119 (33.7%)
   Unknown                                                   18 (5.1%)
  Neoadjuvant treatment                                      
   No                                                        298 (84.4%)
   Yes                                                       52 (14.7%)
   Unknown                                                   3 (0.8%)

Smoking history was assigned based on the CDC definitions (Accessed on Jun 29, 2010. <http://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm>)

Never smoker: An adult who has never smoked, or who has smoked less than 100 cigarettes in his or her lifetime. Former smoker: An adult who has smoked at least 100 cigarettes in his or her lifetime but who had quit smoking at the time of interview. Current smoker: An adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes.

According to the American Joint Committee on Cancer Staging Manual 6th edition.

Recurrence-free survival and overall survival {#s2_2}
---------------------------------------------

We further correlated the expression levels of IGF-1R and pIGF-1R with clinicopathological characteristics and patient survival. The median follow-up times were 6.8 and 5.3 years for the TMA I and TMA II datasets, respectively. The expression levels of IGF-1R and pIGF-1R/IR were evaluated as continuous variables using the Cox Proportional Hazard model. The univariate analysis of the hazard ratios of the biomarkers for OS and RFS are summarized in Table [3](#T3){ref-type="table"} (TMA I) and Table [4](#T4){ref-type="table"} (TMA II). Among the baseline clinical characteristics, the univariate analyses revealed that female sex (only in TMA II), and early cancer stage were significantly associated with improved OS (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). In addition, the analyses also revealed that increased cytoplasmic IGF-1R expression was associated with decreased RFS in NSCLC patients (only in TMA II) (Table [4](#T4){ref-type="table"}). After adjusting for age, gender, histology and stage, a multivariate analysis was performed to determine whether these biomarker expression levels were independent prognostic factors in this population. Neither IGF-1R nor pIGF-1R expression was a significant marker for OS and RFS in the multivariate analysis (data not shown).

###### Univariate analyses of clinical prognostic factors and biomarkers (TMA I)

  Variable                  HR for OS (95% CI)    p-value   HR for RFS (95% CI)   p-value[\*](#tfn_005){ref-type="table-fn"}
  ------------------------- --------------------- --------- --------------------- --------------------------------------------
  Age                       .997 (.979-1.015)     .723      1.040 (1.025-1.056)   \<.0001
  Gender (M vs.F)           .813 (.549-1.203)     .300      1.324 (.981-1.786)    .066
  Race (white vs. other)    2.123 (1.261-3.574)   .005      1.043 (.640-1.699)    .867
  Smoker (Ever vs. never)   .669 (418-1.072)      .095      1.136 (.754-1.712)    .542
  Histology (ADC vs. SCC)   .946 (.626-1.430)     .792      1.442 (1.068-1.949)   .017
  Stage (vs. I)                                                                   
   II                       2.005 (1.201-3346)    .008      1.566 (1.069-2.293)   .021
   III/IV                   4.106 (2.557-6.593)   \<.001    2.707 (1.365-5.370)   .004
  IGF-1R                                                                          
   cytoplasmic              .998 (.993-1.003)     .381      1.000 (.997-1.003)    .961
   membrane                 .995 (.988-1.003)     .238      1.000 (.995-1.005)    .962
  p-IGF-IR/1R                                                                     
   cytoplasmic              1.008 (.987-1.030)    .444      1.011 (.996-1.026)    .141
   membrane                 1.004 (.999-1.009)    .157      1.004 (.999-1.008)    .099

Univariate p-values are based on Cox Proportional Hazard Model.

Abbreviation: HR -- hazard ratio, OS -- overall survival, RFS -- recurrence-free survival, CI -- confidence interval, ADC -- adenocarcinoma, SCC -- squamous cell carcinoma, IR -- insulin receptor and IGF-1R -- insulin-like growth factor 1 receptor.

###### Univariate analyses of clinical prognostic factors and biomarkers (TMA II)

  Variable                  HR for OS (95% CI)    p-value    HR for RFS (95% CI)   p-value[\*](#tfn_006){ref-type="table-fn"}
  ------------------------- --------------------- ---------- --------------------- --------------------------------------------
  Age                       1.015 (0.998-1.031)   0.08       1.007 (0.993-1.022)   0.31
  Gender (M vs.F)           1.468 (1.067-2.020)   0.0186     1.317 (0.997-1.740)   0.053
  Race (white vs. other)    0.747 (0.457-1.222)   0.245      0.784 (0.504-1.222)   0.28
  Smoker                                                                           
  Former vs. Never          1.045 (0.597-1.828)   0.88       1.081 (0.667-1.751)   0.75
  Current vs. Never         1.219 (0.698-2.129)   0.49       1.108 (0.681-1.803)   0.68
  Histology (ADC vs. SCC)   0.831 (0.600-1.151)   0.27       0.809 (0.609-1.074)   0.14
  Stage (vs. I)                                                                    
   II                       1.608 (1.090-2.374)   0.0157     1.73 (1.226-2.440)    0.0018
   IIIA                     2.399 (1.613-3.570)   \<0.0001   2.734 (1.930-3.872)   \<0.0001
  IGF-IR                                                                           
   cytoplasmic              1.003 (0.999-1.007)   0.19       1.004 (1.000-1.008)   0.034
   membrane                 1.002 (0.992-1.011)   0.70       1.001 (0.992-1.010)   0.88
  p-IGF-112/IR                                                                     
   cytoplasmic              0.997 (0.985-1.010)   0.50       0.990 (0.978-1.003)   0.12
   membrane                 0.998 (0.993-1.003)   0.41       0.997 0.992-1.001     0.16

Univariate *p*-values are based on Cox Proportional Hazard Model

Abbreviations: HR = Hazard Ratio, CI = Confidence interval, OS = overall survival, RFS: relapse-free survival.

TCGA data analysis on IGF-1R mRNA and protein expression {#s2_3}
--------------------------------------------------------

A total of three lung cancer studies were identified from the TCGA Research Network portal including TCGA provisional data, TCGA Nature 2012, and TCGA Nature 2014 data \[[@R15], [@R16]\] for IGF-1R mRNA and protein expression. No information was available for pIGF-1R mRNA or protein expression from the database. In general, upregulation of IGF-1R mRNA was reported for both ADC and SCC, ranging from 5.3% to 6.7%. Significant differences in OS (Fig. [3A](#F3){ref-type="fig"}) and DFS (Fig. [3B](#F3){ref-type="fig"}) were observed in a study including ADC patients; the median survival time was significantly shorter for cases with increased IGF-1R mRNA expression than for those without changes (OS median survival 26.51 vs. 47.77 months, *P* = 0.017; DFS median survival 17.44 vs. 37.65 months, *P* = 0.045). Alteration in IGF-1R protein expression was identified in 4.6% of cases with SCC from TCGA provisional data (*N* = 195). However, the changes were not associated with statistically significant changes in survival. No changes in protein expression were identified from cases with ADC.

###### Kaplan--Meier overall survival (OS) and disease-free survival (DFS) curves for ADC patients with (red line) or without (blue line) increases in IGF-1R mRNA expression based on TCGA biospecimens and clinical data

(**A**) OS and (**B**) DFS.
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DISCUSSION {#s3}
==========

In this study, we performed an IHC analysis of the expression patterns of IGF-1R and pIGF-1R in patients with NSCLC using two large independent TMAs and publicly available query data known as the TCGA Research Network data accessible from the cBioPortal \[[@R15], [@R16]\]. Findings from our study indicated the prognostic value of IGF-1R mRNA expression in patients with ADC only from the TCGA data. The clinical development of IGF-1R inhibitors is ongoing \[[@R5], [@R17]\]. To select patients who would be most likely to benefit from these agents, an analysis of target protein expression and the identification of a specific population are required. Given the limited amount of preclinical data on expression patterns or predictors of responses to anti-IGF-1R, antisense RNA, or microRNA, research findings such as those presented in this study are needed to provide insight into the potential prognostic values of these biomarkers.

The IGF-1R pathway plays a critical role in tumorigenesis, angiogenesis, metastasis, and resistance to existing forms of anti-cancer therapy. Accordingly, a variety of strategies to target IGF-1R have been in preclinical or clinical stages for the treatment of cancer patients. However, the mechanisms causing their overexpression in NSCLC are not clear. Inappropriate expression of growth factors or their receptors causes a decrease in the requirement for exogenous growth factors to support the growth and progression of tumors \[[@R18]\]. Dysregulated activation of the IGF-1R pathway by ectopic overexpression of IGF-1R in murine hemopoietic cells causes these cells to gain independence from growth factor requirements and have an increase in resistance to apoptosis \[[@R19]\]. An aberrant regulation of IGF-1R enables MIA PaCa-2 pancreatic cancer cells to escape rapidly from quiescence, makes them growth factor independent, and promotes survival during unfavorable conditions \[[@R20]\].

In lung cancer, elevated plasma levels of IGF-1 have been associated with an increased risk of the disease \[[@R21]\]. Conversely, high plasma levels of insulin-like growth factor binding protein 3 (IGFBP-3) have been associated with a reduced risk \[[@R22]\]. We have previously demonstrated loss of IGFBP-3 expression in early-stage NSCLC \[[@R23]\]. We further reported that hypermethylation of the IGFBP-3 promoter is a frequent abnormality in NSCLC, which is one mechanism that silences IGFBP-3 expression in lung cancers, particularly NSCLC \[[@R24]\]. Recently, we showed that the overexpression of IGF-1 predicts poor survival among patients with NSCLC, especially those with ADC \[[@R25]\]. The main components of the IGF axis also include IGF-1R and its highly structurally conserved family member, insulin receptor (IR). Overexpression of IGF-1R has been found in NSCLC cell lines \[[@R26]\]. A previous study implied that high IGF-1R expression is associated with poor survival in surgically treated NSCLC patients \[[@R27]\]. We have also shown high levels of IGF-1R and IR expression in NSCLC \[[@R28]\]. In this study, we observed the impact of IR as an independent predictive marker of NSCLC survival. However, IGF-1R expression did not have significant impact on RFS and OS of the patients. Similarly, previous studies do not consistently support a definite impact of IGF-1R protein expression on survival of NSCLC \[[@R6], [@R7], [@R11]\].

Based on these controversial findings, we investigated patterns of IGF-1R expression and their association with patient survival. Although previous studies with a relatively small sample size did not identify an association of IGF-1R protein expression with histology in NSCLC samples \[[@R18], [@R29]\], recent reports have demonstrated an association between high IGF-1R expression and squamous histology \[[@R7], [@R11], [@R12], [@R19]\]. Consistent with the previous findings, we observed a significant association between high IGF-1R expression and squamous histology in the present study. However, no significant difference was found in survival between the high-IGF-1R-expression and low-expression groups even though various exploratory cut-off values were employed.

A second level of regulation of IGF-1R expression is upregulation of *IGF-1R* mRNA expression. The IGF-1R gene copy number was evaluated in previous studies. Fluorescent in situ hybridization (FISH) analysis revealed that the IGF-1R gene copy number was increased in a substantial proportion of NSCLC samples (27%, using criteria developed for *EGFR* gene copy number assessment) \[[@R12]\]. A high *IGF-1R* gene copy number has positive prognostic value in NSCLC patients in the study \[[@R11]\]. Consistent with the results from the previous study, our TCGA data analysis revealed increased mRNA levels in NSCLC patients. Moreover, increased levels of mRNA were significantly associated with reductions in OS and DFS of NSCLC patients, especially those with ADC. This suggested that, possibly, the stability of IGF-1R mRNA transcripts in NSCLC cells is regulated by some factor(s) present in the cells. A previous study suggested that stabilization of IGF-1R mRNA via a lack of the unidentified factors that degrade IGF-1R mRNA contributes to aberrant and constitutive activation of this receptor \[[@R20]\].

In conclusion, using large-scale TMAs and TCGA data, we have determined the expression patterns of IGF-1R and pIGF-1R and their association with clinicopathological characteristics. We show that pIGF-1R and IGF-1R expression was higher in patients with SCC than in those with ADC. In addition, we show the lack of prognostic impact of these biomarkers on survival in patients with NSCLC. In contrast, high levels of IGF-1R mRNA appeared to predict decreased survival of patients with NSCLC. IGF-1R overexpression has been suggested to serve as a predictive biomarker of the response to anti-IGF-1R antibodies, such as R1507 \[[@R21]\] and figitumumab \[[@R22]\]. Previous studies also interrogated *IGF-1R* gene copy number status in a panel of NSCLC cell lines and found cell lines with high *IGF-1R* copy number were significantly more sensitive to the *IGF-1R* antibody R1507 compared with those with low *IGF-1R* copy number \[[@R7]\], suggesting the potential value of IGF-1R gene copy number as a predictive marker for anti-IGF-1R monoclonal antibody. These previous results and our current findings suggest that the IGF-1R mRNA level could be a useful predictive biomarker in identifying subsets of NSCLC patients who may be candidates for future IGF-1R inhibitor-based clinical trials.

PATIENTS AND METHODS {#s4}
====================

Patient characteristics {#s4_1}
-----------------------

The patient baseline characteristics from the two tissue microarray (TMA) sets are presented in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Detailed clinical and pathological information were available for most of these cases and included patients\' demographic data, smoking history (never smokers or ever smokers, patients who had smoked at least 100 cigarettes in their lifetime), pathologic tumor-node-metastasis (TNM) staging, OS time, and recurrence-free survival (RFS) time. Gender was well balanced in both of the datasets, and adenocarcinoma (ADC) patients represented nearly two-thirds of each dataset. Most patients had early-stage lung cancer and were former or current smokers. The tissue banking and research conduct were approved by the M.D. Anderson Cancer Center Institutional Review Board. All patients provided informed consent, and any personal identifiers were removed from the database.

Case selection and TMA construction {#s4_2}
-----------------------------------

We obtained archived formalin-fixed and paraffin-embedded samples from previously described tissue banks at The University of Texas M.D. Anderson Cancer Center (Houston, TX) \[[@R23]\]. The tissue specimens were originally collected between 1997 and 2005 and were classified using the 2004 World Health Organization classification system \[[@R25]\]. We selected specimens to construct two TMA sets. TMA set I comprised NSCLC specimens obtained from patients who underwent surgery at the M.D. Anderson Cancer Center in 1997--2003, and TMA set II comprised NSCLC tumor specimens obtained from patients who underwent surgery at the same institution in 2003--2005. Only patients with available staging information were included in the analyses (*N* = 352 for TMA I and *N* = 353 for TMA II). To clarify the impact of biomarker expression on resectable NSCLC survival, patients with advanced stages, i.e., stages IIIB and IV, or patients in early stages who received a suboptimal surgery, such as wedge resection, were excluded from TMA II in the survival analysis (*N* = 270). After histological examination of the NSCLC specimens, the NSCLC TMAs were constructed by removing three 1 mm-diameter cores from each tumor at three different sites (periphery, intermediate and central tumor sites). The TMAs were prepared with a manual tissue arrayer (Advanced Tissue Arrayer ATA100, Chemicon International, Temecula, CA).

Immunohistochemistry and analysis {#s4_3}
---------------------------------

We previously observed significantly higher levels of IGF-1R in SCC specimens than in ADC specimens \[[@R26]\]. Thus, we investigated the activation of the IGF-1R pathway in NSCLC as well as the expression of IGF-1R and pIGF-1R by performing immunohistochemical (IHC) analysis using TMA I and TMA II, which were associated with median follow-up times of 6.8 and 5.3 years, respectively. The primary antibodies for IHC analysis were purchased from Cell Signal Technology (IGF-1R and pIGF-1R). For pIGF-1R expression in the tissue samples, we used antibodies against pIGF-1R (Tyr 1135/1136)/pIR, Tyr1162/1163) employed previously \[[@R26]\].

Details of the IHC protocol have been described previously \[[@R23]\]. Expression was quantified by two independent observers (C.B. and I.I.W.). For each patient, the results from three cores were averaged. The results for each observer were averaged to obtain the final IHC score. Cytoplasmic, membranous and nuclear expression were quantified using a four-value intensity score (0, 1+, 2+, and 3+) and the percentage (0--100%) of the extent of reactivity. Next, the expression score was obtained by multiplying the intensity score and reactivity extension values (range, 0--300). A tumor sample was considered positive if the score was above the median and negative otherwise.

IGF-1R mRNA and protein expression and survival from The Cancer Genome Atlas (TCGA) data {#s4_4}
----------------------------------------------------------------------------------------

We searched the TCGA data portal to identify alterations in IGF-1R mRNA and protein expression, and the relationships between changes in the expression and OS or disease-free survival (DFS) were evaluated. The TCGA Research Network portal was used for evaluating alterations in mRNA and protein expression, and clinical data for comparing survival; these are available at www.cbioportal.org/public-portal \[[@R27], [@R28]\].

Statistical analysis {#s4_5}
--------------------

The summary statistics for the biomarker expression levels according to patient baseline characteristics were computed. The Wilcoxon rank sum test and Kruskal--Wallis test were used to compare biomarker expression among different subgroups defined by categorical variables, such as histology. The OS and RFS of each subgroup of patients were determined by the Kaplan--Meier method and compared using the log-rank test. Cox proportional hazard models were used for multivariate analyses. All statistical tests were two-sided, and *P* ≤ 0.05 was considered significant. The association between changes in IGF-1R mRNA expression and OS or DFS was evaluated by a log-rank test and provided by the TCGA Research Network \[[@R27], [@R28]\].
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